Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid'

April 27, 2026 10:48 AM EDT

TD Cowen analyst Joseph Thome reiterated a Buy rating on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "NTLA released Ph. III data of its in vivo gene editing candidate lonvo-z for the treatment of HAE this morning. The trial hit both primary and... More